US regulators have approved Sanofi’s Quadracel vaccine for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in children aged between four and six years old.

Approval is based on data from a Phase III study showing that the jab has similar safety and immunogenicity profiles as those of separately administered DAPTACEL and IPOL vaccines.

Quadracel provides healthcare providers with a new combination vaccine that potentially reduces the number of vaccine injections needed in children of this age, said David Greenberg, US Scientific and Medical Affairs lead at Sanofi Pasteur. 

“Our goal is to help remove barriers to timely immunisation and we think this combination vaccine could help ensure children are getting vaccinated in line with current recommendations,” he noted.